{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,8]],"date-time":"2026-08-08T00:45:20Z","timestamp":1786149920741,"version":"build-2736575974"},"reference-count":38,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,6,23]],"date-time":"2026-06-23T00:00:00Z","timestamp":1782172800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","gynecologiconcology-online.net","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Gynecologic Oncology"],"published-print":{"date-parts":[[2026,8]]},"DOI":"10.1016\/j.ygyno.2026.06.018","type":"journal-article","created":{"date-parts":[[2026,6,27]],"date-time":"2026-06-27T00:35:42Z","timestamp":1782520542000},"page":"67-73","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["A second chance for the second look: Feasibility of laparoscopic HIPEC at the conclusion of upfront treatment for epithelial ovarian cancer"],"prefix":"10.1016","volume":"211","author":[{"given":"Ana","family":"Kouri","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anya","family":"Menzies","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kristen","family":"Stearns","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christine","family":"McGough","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fang-Chi","family":"Hsu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Janelle P.","family":"Darby","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael G.","family":"Kelly","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Samuel S.","family":"Lentz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laurel K.","family":"Berry","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.ygyno.2026.06.018_bb0005","first-page":"10","article-title":"Cancer statistics, 2025","volume":"75","author":"Siegel","year":"2025","journal-title":"CA Cancer J. Clin."},{"issue":"10","key":"10.1016\/j.ygyno.2026.06.018_bb0010","doi-asserted-by":"crossref","first-page":"833","DOI":"10.1016\/j.annonc.2023.07.011","article-title":"Newly diagnosed and relapsed epithelial ovarian cancer: ESMO clinical practice guideline for diagnosis, treatment and follow-up","volume":"34","author":"Gonzalez-Martin","year":"2023","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.ygyno.2026.06.018_bb0015","author":"N.C.C. Network"},{"issue":"14","key":"10.1016\/j.ygyno.2026.06.018_bb0020","doi-asserted-by":"crossref","first-page":"1278","DOI":"10.1001\/jama.2025.9495","article-title":"Ovarian cancer: a review","volume":"334","author":"Caruso","year":"2025","journal-title":"JAMA"},{"issue":"7","key":"10.1016\/j.ygyno.2026.06.018_bb0025","doi-asserted-by":"crossref","first-page":"868","DOI":"10.1200\/JCO-24-02589","article-title":"Neoadjuvant chemotherapy for newly diagnosed, advanced ovarian Cancer: ASCO guideline update","volume":"43","author":"Gaillard","year":"2025","journal-title":"J. Clin. Oncol."},{"issue":"1","key":"10.1016\/j.ygyno.2026.06.018_bb0030","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1056\/NEJMoa052985","article-title":"Intraperitoneal cisplatin and paclitaxel in ovarian cancer","volume":"354","author":"Armstrong","year":"2006","journal-title":"N. Engl. J. Med."},{"issue":"1","key":"10.1016\/j.ygyno.2026.06.018_bb0035","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/0090-8258(85)90118-0","article-title":"Clinical pharmacology of intraperitoneal cisplatin","volume":"20","author":"Lopez","year":"1985","journal-title":"Gynecol. Oncol."},{"issue":"5","key":"10.1016\/j.ygyno.2026.06.018_bb0040","doi-asserted-by":"crossref","first-page":"548","DOI":"10.1080\/02656736.2017.1283066","article-title":"Current status and future prospects of hyperthermic intraoperative intraperitoneal chemotherapy (HIPEC) clinical trials in ovarian cancer","volume":"33","author":"Cowan","year":"2017","journal-title":"Int. J. Hyperth."},{"issue":"3 Pt 2","key":"10.1016\/j.ygyno.2026.06.018_bb0045","doi-asserted-by":"crossref","first-page":"S122","DOI":"10.1006\/gyno.1994.1350","article-title":"Second-look laparotomy in ovarian cancer","volume":"55","author":"Creasman","year":"1994","journal-title":"Gynecol. Oncol."},{"issue":"3","key":"10.1016\/j.ygyno.2026.06.018_bb0050","doi-asserted-by":"crossref","first-page":"994","DOI":"10.1200\/JCO.1997.15.3.994","article-title":"Surgical second look in ovarian cancer: a randomized study in patients with laparoscopic complete remission--a Northeastern Oncology Cooperative Group-Ovarian Cancer Cooperative Group study","volume":"15","author":"Nicoletto","year":"1997","journal-title":"J. Clin. Oncol."},{"issue":"1","key":"10.1016\/j.ygyno.2026.06.018_bb0055","doi-asserted-by":"crossref","first-page":"148","DOI":"10.1016\/S0959-8049(97)00370-5","article-title":"Intraperitoneal cisplatin with regional hyperthermia in advanced ovarian cancer: pharmacokinetics and cisplatin-DNA adduct formation in patients and ovarian cancer cell lines","volume":"34","author":"van de Vaart","year":"1998","journal-title":"Eur. J. Cancer"},{"issue":"3","key":"10.1016\/j.ygyno.2026.06.018_bb0060","doi-asserted-by":"crossref","first-page":"230","DOI":"10.1056\/NEJMoa1708618","article-title":"Hyperthermic intraperitoneal chemotherapy in ovarian cancer","volume":"378","author":"van Driel","year":"2018","journal-title":"N. Engl. J. Med."},{"issue":"11","key":"10.1016\/j.ygyno.2026.06.018_bb0065","doi-asserted-by":"crossref","first-page":"1133","DOI":"10.1001\/jamasurg.2023.3944","article-title":"Hyperthermic intraperitoneal chemotherapy after interval cytoreductive surgery for patients with advanced-stage ovarian cancer who had received neoadjuvant chemotherapy","volume":"158","author":"Lee","year":"2023","journal-title":"JAMA Surg."},{"issue":"12","key":"10.1016\/j.ygyno.2026.06.018_bb0070","doi-asserted-by":"crossref","first-page":"1551","DOI":"10.1016\/S1470-2045(24)00531-X","article-title":"Hyperthermic intraperitoneal chemotherapy for recurrent ovarian cancer (CHIPOR): a randomised, open-label, phase 3 trial","volume":"25","author":"Classe","year":"2024","journal-title":"Lancet Oncol."},{"issue":"11","key":"10.1016\/j.ygyno.2026.06.018_bb0075","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejso.2025.110424","article-title":"Hyperthermic intraperitoneal chemotherapy (HIPEC) for primary advanced-stage or recurrent ovarian cancer: a systematic review and meta-analysis of randomized control trials","volume":"51","author":"Guerra","year":"2025","journal-title":"Eur. J. Surg. Oncol."},{"issue":"10","key":"10.1016\/j.ygyno.2026.06.018_bb0080","doi-asserted-by":"crossref","first-page":"1109","DOI":"10.1016\/S1470-2045(23)00396-0","article-title":"Cytoreductive surgery with or without hyperthermic intraperitoneal chemotherapy in patients with advanced ovarian cancer (OVHIPEC-1): final survival analysis of a randomised, controlled, phase 3 trial","volume":"24","author":"Aronson","year":"2023","journal-title":"Lancet Oncol."},{"issue":"5","key":"10.1016\/j.ygyno.2026.06.018_bb0085","doi-asserted-by":"crossref","first-page":"1094","DOI":"10.1016\/0002-9378(88)90420-6","article-title":"Recurrence after negative second-look laparotomy for ovarian cancer: analysis of risk factors","volume":"159","author":"Rubin","year":"1988","journal-title":"Am. J. Obstet. Gynecol."},{"issue":"4","key":"10.1016\/j.ygyno.2026.06.018_bb0090","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1007\/s11864-015-0329-5","article-title":"The role of hyperthermic intraperitoneal intraoperative chemotherapy in ovarian cancer","volume":"16","author":"van Driel","year":"2015","journal-title":"Curr. Treat. Options in Oncol."},{"issue":"17","key":"10.1016\/j.ygyno.2026.06.018_bb0095","doi-asserted-by":"crossref","first-page":"3194","DOI":"10.1200\/JCO.2003.02.153","article-title":"Phase III trial of carboplatin and paclitaxel compared with cisplatin and paclitaxel in patients with optimally resected stage III ovarian cancer: a gynecologic oncology group study","volume":"21","author":"Ozols","year":"2003","journal-title":"J. Clin. Oncol."},{"issue":"3","key":"10.1016\/j.ygyno.2026.06.018_bb0100","doi-asserted-by":"crossref","first-page":"794","DOI":"10.1016\/j.ygyno.2020.06.487","article-title":"A guide to establishing a hyperthermic intraperitoneal chemotherapy program in gynecologic oncology","volume":"158","author":"Chambers","year":"2020","journal-title":"Gynecol. Oncol."},{"issue":"3","key":"10.1016\/j.ygyno.2026.06.018_bb0105","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1007\/s10147-025-02700-w","article-title":"Intraperitoneal chemotherapy is now back for ovarian cancer","volume":"30","author":"Fujiwara","year":"2025","journal-title":"Int. J. Clin. Oncol."},{"issue":"2","key":"10.1016\/j.ygyno.2026.06.018_bb0110","doi-asserted-by":"crossref","first-page":"234","DOI":"10.1016\/j.ygyno.2022.08.015","article-title":"HIPEC after neoadjuvant chemotherapy is associated with acceptable toxicity and favorable quality of life in newly diagnosed advanced ovarian cancer patients","volume":"167","author":"Menzies","year":"2022","journal-title":"Gynecol. Oncol."},{"issue":"20","key":"10.1016\/j.ygyno.2026.06.018_bb0115","doi-asserted-by":"crossref","DOI":"10.3390\/jcm10204757","article-title":"Laparoscopic heated intraperitoneal chemotherapy in the treatment of carcinomatosis of gastric adenocarcinoma origin","volume":"10","author":"White","year":"2021","journal-title":"J. Clin. Med."},{"issue":"1","key":"10.1016\/j.ygyno.2026.06.018_bb0120","doi-asserted-by":"crossref","DOI":"10.3390\/cancers15010279","article-title":"Laparoscopic Cytoreduction Combined with Hyperthermic Intraperitoneal Chemotherapy (HIPEC) in Peritoneal Surface Malignancies (PSM): Italian PSM oncoteam evidence and literature review","volume":"15","author":"Sommariva","year":"2022","journal-title":"Cancers (Basel)"},{"issue":"1","key":"10.1016\/j.ygyno.2026.06.018_bb0125","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1007\/s00464-018-6265-2","article-title":"Feasibility of hand-assisted laparoscopic cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for peritoneal surface malignancy","volume":"33","author":"Salti","year":"2019","journal-title":"Surg. Endosc."},{"issue":"10","key":"10.1016\/j.ygyno.2026.06.018_bb0130","doi-asserted-by":"crossref","first-page":"6430","DOI":"10.1007\/s00464-025-12026-3","article-title":"Short-term outcomes of laparoscopic versus open cytoreductive surgery: a propensity score matching analysis","volume":"39","author":"Aulicino","year":"2025","journal-title":"Surg. Endosc."},{"issue":"7","key":"10.1016\/j.ygyno.2026.06.018_bb0135","doi-asserted-by":"crossref","first-page":"5644","DOI":"10.1007\/s00464-022-09589-w","article-title":"Laparoscopic cytoreductive surgery and hyperthermic intraperitoneal chemotherapy: a prospective clinical trial and comparative analysis","volume":"37","author":"Cho","year":"2023","journal-title":"Surg. Endosc."},{"issue":"1","key":"10.1016\/j.ygyno.2026.06.018_bb0140","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1007\/s00464-023-10508-w","article-title":"Laparoscopic versus open approach for interval cytoreductive surgery and hyperthermic intraperitoneal chemotherapy (HIPEC) in advanced epithelial ovarian cancer: a matched comparative study","volume":"38","author":"Duran-Martinez","year":"2024","journal-title":"Surg. Endosc."},{"issue":"2","key":"10.1016\/j.ygyno.2026.06.018_bb0145","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1007\/s002800050870","article-title":"A pilot phase I trial of continuous hyperthermic peritoneal perfusion with high-dose carboplatin as primary treatment of patients with small-volume residual ovarian cancer","volume":"43","author":"Steller","year":"1999","journal-title":"Cancer Chemother. Pharmacol."},{"issue":"16","key":"10.1016\/j.ygyno.2026.06.018_bb0150","doi-asserted-by":"crossref","first-page":"1380","DOI":"10.1200\/JCO.18.01568","article-title":"Randomized trial of intravenous versus intraperitoneal chemotherapy plus bevacizumab in advanced ovarian carcinoma: an NRG Oncology\/Gynecologic Oncology Group study","volume":"37","author":"Walker","year":"2019","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.ygyno.2026.06.018_bb0155","article-title":"Assessment of travel distance for hyperthermic intraperitoneal chemotherapy in women with ovarian cancer","volume":"40","author":"Chambers","year":"2022","journal-title":"Gynecol. Oncol. Rep."},{"issue":"8","key":"10.1016\/j.ygyno.2026.06.018_bb0160","doi-asserted-by":"crossref","first-page":"1394","DOI":"10.1002\/ijc.34124","article-title":"Effect of HIPEC according to HRD\/BRCAwt genomic profile in stage III ovarian cancer: results from the phase III OVHIPEC trial","volume":"151","author":"Koole","year":"2022","journal-title":"Int. J. Cancer"},{"key":"10.1016\/j.ygyno.2026.06.018_bb0165","article-title":"Hyperthermic intraperitoneal chemotherapy (HIPEC) after primary debulking surgery in advanced epithelial ovarian cancer: is BRCA mutational status making the difference?","volume":"31","author":"Ghirardi","year":"2022","journal-title":"Cancer Treat. Res. Commun."},{"issue":"4","key":"10.1016\/j.ygyno.2026.06.018_bb0170","doi-asserted-by":"crossref","first-page":"382","DOI":"10.1001\/jama.2012.20","article-title":"Association between BRCA1 and BRCA2 mutations and survival in women with invasive epithelial ovarian cancer","volume":"307","author":"Bolton","year":"2012","journal-title":"JAMA"},{"issue":"11","key":"10.1016\/j.ygyno.2026.06.018_bb0175","doi-asserted-by":"crossref","first-page":"981","DOI":"10.1016\/j.annonc.2024.08.2241","article-title":"Niraparib first-line maintenance therapy in patients with newly diagnosed advanced ovarian cancer: final overall survival results from the PRIMA\/ENGOT-OV26\/GOG-3012 trial","volume":"35","author":"Monk","year":"2024","journal-title":"Ann. Oncol."},{"issue":"26","key":"10.1016\/j.ygyno.2026.06.018_bb0180","doi-asserted-by":"crossref","first-page":"2495","DOI":"10.1056\/NEJMoa1810858","article-title":"Maintenance Olaparib in patients with newly diagnosed advanced ovarian cancer","volume":"379","author":"Moore","year":"2018","journal-title":"N. Engl. J. Med."},{"issue":"25","key":"10.1016\/j.ygyno.2026.06.018_bb0185","doi-asserted-by":"crossref","first-page":"2416","DOI":"10.1056\/NEJMoa1911361","article-title":"Olaparib plus bevacizumab as first-line maintenance in ovarian cancer","volume":"381","author":"Ray-Coquard","year":"2019","journal-title":"N. Engl. J. Med."},{"issue":"23","key":"10.1016\/j.ygyno.2026.06.018_bb0190","doi-asserted-by":"crossref","first-page":"2594","DOI":"10.1200\/JCO.21.00605","article-title":"Secondary cytoreduction and carboplatin hyperthermic intraperitoneal chemotherapy for platinum-sensitive recurrent ovarian cancer: an MSK Team Ovary phase II study","volume":"39","author":"Zivanovic","year":"2021","journal-title":"J. Clin. Oncol."}],"container-title":["Gynecologic Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S009082582602038X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S009082582602038X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,8,8]],"date-time":"2026-08-08T00:34:36Z","timestamp":1786149276000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S009082582602038X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8]]},"references-count":38,"alternative-id":["S009082582602038X"],"URL":"https:\/\/doi.org\/10.1016\/j.ygyno.2026.06.018","relation":{},"ISSN":["0090-8258"],"issn-type":[{"value":"0090-8258","type":"print"}],"subject":[],"published":{"date-parts":[[2026,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"A second chance for the second look: Feasibility of laparoscopic HIPEC at the conclusion of upfront treatment for epithelial ovarian cancer","name":"articletitle","label":"Article Title"},{"value":"Gynecologic Oncology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ygyno.2026.06.018","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}